Sanofi Invests €300 Million in Biologics Manufacturing Facility
Sanofi will invest in its Geel, Belgium facility in order to support its pipeline of monoclonal antibodies.
The French drug maker Sanofi plans to invest €300 million (approximately $341.24 million) into expanding its biologics manufacturing facility located in Geel, Belgium, the company said in a April 19, 2016 press announcement.
Sanofi said it plans to expand its existing production capabilities to support its pipeline of monoclonal antibodies. The company will make several upgrades to the facility including new laboratories for quality control and manufacturing. The investment will add more than 8000 m2 of manufacturing floor space to the facility.
Sanofi and its specialty care business, Sanofi Genzyme, have already invested €600 million (approximately $682.68 million) in the Geel site, which began industrial biotech activities in 2001. The site is currently responsible for the global production of a protein therapy for Pompe disease, a rare, genetic muscular disease that can be fatal. The protein therapy is produced using cell cultures in large bioreactors, followed by a purification process.
Source: Sanofi
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
